Preliminary findings on the expression of plasma CD63, CD62P, and PAI 1 in patients with acute cerebral infarction

To investigate the expression and clinical significance of lysosomal granule glycoprotein 63 (CD63), P-selectin (CD62P) and endothelial cell plasminogen activator inhibitor (PAI-1) in patients with acute cerebral infarction. A total of 106 patients with acute cerebral infarction (ACI) admitted to our hospital from January to July in 2017 were selected as the patient group; 80 healthy subjects for physical examination in our hospital were selected as the control group. The expression levels of serum CD63, CD62P, and PAI-1 of the subjects were detected. The levels of CD63, CD62P, and PAI-1 in the serum of the patient group were significantly higher than those in the control group. There was a positive correlation between serum CD63 and CD62P (r = 0.672, P < 0.05) in the patient group. There was a positive correlation between serum CD63 and PAI-1 (r = 0.643, P < 0.05) in the patient group. There was also a positive correlation between serum CD62P and PAI-1 (r = 0.601, P < 0.05) in the patient group. Moreover, in other subtypes of cerebral infarction, the expression of CD63, CD62P, and PAI-1 was significantly higher than that of lacunar infarction. CD63, CD62P, and PAI-1 are highly expressed in peripheral blood mononuclear cells (PBMC) and serum of patients with ACI, which may be closely related to the occurrence and development of patients with ACI. These indices may be used as indicators of clinical diagnosis and prognosis in patients with ACI.